ClinicalTrials.gg
Not yet recruitingNCT04954989RUBIUpdated Aug 21, 2024

Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers

A Phase 1 interventional study of Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU and Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU in Healthy, sponsored by Megalabs. Not yet recruiting at 1 site in India. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Megalabs · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Open label and monocentric Phase I Clinical Trial, to Determine the Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin for Subcutaneous Use in an Adult Male Population

Read the detailed description

An open label, balanced, randomized, two treatments, two sequences, two periods, single dose, crossover design will be used to study the pharmacokinetics and pharmacodynamics of two different rHuEpo products when administered subcutaneously in healthy subjects.

PK parameters to evaluate shall be AUCt and AUCt to infinity, and Cmax PD parameter shall be erithrocye and reticulocyte counts and hematocrite. Bioequivalence shall be evaluated according to 80-125 T/R rate for 90 % Cmax and AUC for pk and PD parameters.

02

Conditions studied

  • Healthy

Keywords

  • reticulocytes
03

In context

Lead sponsor

Megalabs is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy eligible participants able to read, understand and sign the latest version of the Form (FICF) approved by the Research Ethics Committee (CEP);
  • Male participants aged between 18 and 55 years;
  • Be characterized as a healthy research participant, based on medical history, general physical examination and vital signs, laboratory tests and not indicating any evidence of disease;
  • Present ≥ 18 and ≤ 29.9 Kg/m2;
  • Have a body weight of 60 - 100 kg;
  • Present a negative test for coronavirus.

Exclusion criteria

Exclusion Criteria:

  • Present one or more flu-like symptoms such as: fever (body temperature greater than or equal to 37.8°C), cough, dyspnea, myalgia and fatigue, respiratory symptoms, gastrointestinal symptoms (such as diarrhea) within 7 days prior to the hospital stay (all periods);
  • Having had direct and significant contact, at the medical discretion, with people who tested positive for a coronavirus test within 14 days prior to the hospital stay (all periods);
  • Living in the same household as people who fall into the risk group of worse prognosis for coronavirus infection, such as individuals over 60 years old, individuals with respiratory problems, or those with chronic diseases such as heart or diabetes (all periods );
  • Any clinical condition or laboratory alteration that, at the investigator's discretion, may compromise trial participation, ie:
  • Have an abnormal erythrocyte count (\<4.0 M/mm3 or >5.4 M/mm3);
  • Have an abnormal reticulocyte count (> 3.0%);
  • Have an abnormal count (\< 135,000/μL or > 550,000/μL);
  • Have an abnormal level (\< 13g/dL);
  • Have an abnormal level of hematocrit (\<40% or >54%);
  • Have an abnormal level of ferritin (\< 100 ng/mL or > 336.2 ng/mL);
  • Have an abnormal level of transferrin (\< 200 mg/dL or > 360 mg/dL);
  • Have an abnormal level of transferrin saturation (\<20%)
  • Have abnormal levels of vitamin B12 (\< 130 pg/mL or >868 pg/mL);
  • Present evidence of cardiovascular disorders, particularly arterial hypertension (supine blood pressure > 145 / 90mmHg at baseline);
  • History of venous thrombosis;
  • Participants diagnosed with iron deficiency anemia or clinical history of or hereditary anemia;
  • Clinical history of chronic or acute hemorrhages in the 30 days preceding the start of the trial;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Test rHuEpo in a single subcutaneous application.

    Group T: Test rHuEepo shall be administered subcutaneosly to study participants

    Biological: Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU · Biological: Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU

  • Active comparator
    Reference rHuEpo in a single subcutaneous application.

    Group T: Reference rHuEepo shall be administered subcutaneosly to study participants

    Biological: Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU · Biological: Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU

Interventions

  • BiologicalExperimental Erythropoietin subcutaneous injection single dose of 4,000 IU

    Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously

  • BiologicalActive comparator Erythropoietin subcutaneous injection single dose of 4,000 IU

    Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Evaluation of AUC0-inf

    Area under curve Cp(t) rHuEpo from time zero to infinity

    Time frame: 14 days

  2. Evaluation Cmax

    Maximum plasma concentration for rHuEpo

    Time frame: 14 days

  3. Evaluation of Emax

    maximum increase in reticulocyte count

    Time frame: 14 days

  4. Evaluation of ASEC0-t

    Area under curve reticulocyte count f(t) from time zero to day 14

    Time frame: 14 days

Secondary outcomes

  1. half life

    Compare profiles for T½ between the experimental drug and the comparator.

    Time frame: 14 days

  2. Tmax

    Compare profiles for Tmax between the experimental drug and the comparator.

    Time frame: 14 days

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Dec 2024, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2021
First posted
Jul 8, 2021
StartEst.
Oct 6, 2024
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 2024
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04954989
Lead sponsor
Megalabs
Responsible party
Sponsor
First posted
Jul 8, 2021
Start date
Oct 6, 2024 (estimated)
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Aug 21, 2024

Study contacts

Marcos Giusti, MD
Contact
mgiusti@megalabs.global
+598926838000
Victoria Rodríguez, MD
Contact
vrodriguez@megalabs.global
Satish Kumar, MD
principal investigator · Azidus Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion